4 hours Ago By Defense World Staff
Victory Capital Management Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The firm acquired 410,440 shares of the company’s stock, valued at approximately $7,868,000. Victory Capital Management Inc. owned approximately 0.
52% of Viridian Therapeutics as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors have also recently added to or reduced their stakes in the stock. Great Point Partners LLC raised its position in Viridian Therapeutics by 50.
0% in the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after purchasing an additional 250,000 shares during the period. Lord Abbett & CO.
LLC purchased a new stake in Viridian Therapeutics in the third quarter valued at $8,917,000. JPMorgan Chase & Co. raised its position in Viridian Therapeutics by 218.
5% in the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after purchasing an additional 274,641 shares during the period.
Barclays PLC raised its holdings in shares of Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after buying an additional 66,550 shares during the period.
Finally, Point72 Asset Management L.P. purchased a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at $788,000.
Viridian Therapeutics Stock PerformanceShares of VRDN stock opened at $15.92 on Friday. The business has a 50 day moving average of $17.
43 and a two-hundred day moving average of $19.66. The company has a market cap of $1.
30 billion, a P/E ratio of -3.69 and a beta of 1.05.
The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.
04. Viridian Therapeutics, Inc. has a 52 week low of $11.
40 and a 52 week high of $27.20. Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its earnings results on Thursday, February 27th.
The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.
24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.
16%. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.
05 million. As a group, analysts anticipate that Viridian Therapeutics, Inc. will post -4.
03 EPS for the current year. Analyst Ratings ChangesSeveral equities research analysts recently issued reports on VRDN shares. Needham & Company LLC reiterated a “buy” rating and issued a $38.
00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen started coverage on Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating for the company.
Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th.
Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th.
Finally, HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock.
Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.70.Check Out Our Latest Research Report on Viridian TherapeuticsViridian Therapeutics Profile (Free Report)Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases.
The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.Featured ArticlesFive stocks we like better than Viridian Therapeutics3 Must-Buy Warren Buffett Stocks for Volatile TimesRubrik Stock’s V-Bottom Reversal Signals a Major Rally AheadWhat is a Dividend Harvesting Strategy and How Can Investors Profit from it?How Super Micro Computer Stock Is Defying the Market Sell-OffWhy Invest in 5G? How to Invest in 5G Stocks AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report)..
